Loading…
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing, vaccinations and other preventive care, and a range of consultative services designed to protect employees from workplace hazards. The company was founded in 1979 and is based in Addison, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.2B | $409M | $166M | $197M | 42.3% | 13.9% | -0.1% |
| 2024 | $1.9B | $368M | $167M | $210M | 60.4% | 3.4% | -7.4% |
| 2023 | $1.8B | $360M | $180M | $165M | 15.6% | 6.6% | 7.9% |
| 2022 | $1.7B | $330M | $167M | $228M | 17.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,724.36 | 1,838.08 | 1,900.19 | 2,163.42 |
| Operating Revenue | - | 1,685.95 | 1,796.20 | 1,856.49 | 2,115.90 |
| Cost Of Revenue | - | 1,242.50 | 1,325.65 | 1,372.22 | 1,550.32 |
| Gross Profit | - | 481.86 | 512.43 | 527.98 | 613.09 |
| Operating Expense | - | 223.33 | 224.80 | 223.21 | 279.10 |
| Selling General And Administration | - | 149.98 | 152 | 156.32 | 203.30 |
| Total Expenses | - | 1,465.83 | 1,550.45 | 1,595.43 | 1,829.42 |
| Operating Income | - | 258.53 | 287.63 | 304.76 | 333.99 |
| Total Operating Income As Reported | - | 258.53 | 287.63 | 304.76 | 333.99 |
| EBITDA | - | 330.20 | 360.16 | 368.26 | 408.93 |
| Normalized EBITDA | - | 330.20 | 360.16 | 368.26 | 409.81 |
| EBIT | - | 256.54 | 287.10 | 301.09 | 333.12 |
| Interest Expense | - | 31.64 | 44.47 | 69.69 | 109.29 |
| Net Interest Income | - | -31.64 | -44.47 | -69.69 | -109.29 |
| Other Non Operating Income Expenses | - | -0.42 | 0 | - | - |
| Other Income Expense | - | -1.99 | -0.53 | -3.68 | -0.88 |
| Interest Expense Non Operating | - | 31.64 | 44.47 | 69.69 | 109.29 |
| Net Non Operating Interest Income Expense | - | -31.64 | -44.47 | -69.69 | -109.29 |
| Pretax Income | - | 224.90 | 242.63 | 231.39 | 223.83 |
| Tax Provision | - | 52.65 | 57.89 | 59.50 | 50.98 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | -0.20 |
| Net Income Continuous Operations | - | 172.24 | 184.74 | 171.90 | 172.85 |
| Net Income From Continuing And Discontinued Operation | - | 166.73 | 179.95 | 166.54 | 166.42 |
| Net Income From Continuing Operation Net Minority Interest | - | 166.73 | 179.95 | 166.54 | 166.42 |
| Net Income | - | 166.73 | 179.95 | 166.54 | 166.42 |
| Net Income Common Stockholders | - | 166.73 | 179.95 | 166.54 | 166.42 |
| Net Income Including Noncontrolling Interests | - | 172.24 | 184.74 | 171.90 | 172.85 |
| Normalized Income | - | 166.73 | 179.95 | 166.54 | 167.09 |
| Diluted NI Availto Com Stockholders | - | 166.73 | 179.95 | 166.54 | 166.42 |
| Basic Average Shares | - | 126.59 | 126.59 | 114.20 | 128.01 |
| Diluted Average Shares | - | 126.59 | 126.59 | 114.20 | 128.01 |
| Reconciled Depreciation | - | 73.67 | 73.05 | 67.18 | 75.82 |
| Reconciled Cost Of Revenue | - | 1,242.50 | 1,325.65 | 1,372.22 | 1,550.32 |
| Total Unusual Items | - | 0 | 0 | 0 | -0.88 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | 0 | -0.88 |
| Minority Interests | - | -5.52 | -4.80 | -5.35 | -6.43 |
| Special Income Charges | - | 0 | 0 | 0 | -0.88 |
| Gain On Sale Of Business | 2.15 | 0 | 0 | - | - |
| Other Special Charges | - | - | - | - | 0.88 |
| Depreciation Amortization Depletion Income Statement | - | 73.67 | 73.05 | 67.18 | 75.82 |
| Depreciation And Amortization In Income Statement | - | 73.67 | 73.05 | 67.18 | 75.82 |
| General And Administrative Expense | - | 149.98 | 152 | 156.32 | 203.30 |
| Other Gand A | - | 149.98 | 152 | 156.32 | 203.30 |
| Other Operating Expenses | - | -0.31 | -0.25 | -0.28 | -0.02 |
| Earnings From Equity Interest | - | -1.58 | -0.53 | -3.68 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Concentra Group Holdings Parent, Inc.this co. | CON | $3.2B | 19.16↓ discount | 8.11 | 42.3% | 12.74 |
| Merit Medical Systems, Inc. | MMSI | $3.8B | 29.27 | 2.37 | 8.1% | 12.46 |
| ACADIA Pharmaceuticals Inc. | ACAD | $3.7B | 9.51 | 3.03 | 31.9% | 30.83 |
| Organon & Co. | OGN | $3.5B | 18.82 | 4.68 | 24.9% | 8.98 |
| ICU Medical, Inc. |
| 2021 | - | - | - | - | - | - | - |
| ICUI |
| $3.4B |
| 4607.08 |
| 1.59 |
| 0.0% |
| 14.73 |
| Integer Holdings Corporation | ITGR | $3.1B | 30.63 | 1.80 | 5.9% | 15.20 |
| Arcus Biosciences, Inc. | RCUS | $3.1B | -8.80 | 4.92 | -55.9% | -8.94 |
| National HealthCare Corporation | NHC | $2.9B | 24.47 | 2.75 | 11.2% | 13.71 |
| Privia Health Group, Inc. | PRVA | $2.7B | 117.50 | 3.65 | 3.1% | 50.35 |
| Peer Median | - | 26.87 | 2.89 | 7.0% | 14.22 | |